@article{973291df56db4c5e81637a4a289a044e,
title = "Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function",
keywords = "SGLT2 (sodium-glucose cotransporter 2) inhibitor, cardiovascular disease, chronic kidney disease, diabetes, diabetic kidney disease, heart failure",
author = "{van Raalte}, {Daniel H.} and Heerspink, {Hiddo Lambers}",
note = "Funding Information: DV serves on advisory boards of Boehringer Ingelheim, Eli Lilly Alliance, Sanofi, Merck Sharp & Dohme (MSD) and Bayer, and received research grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Sanofi, and MSD. HH has served as a consultant for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Pharma, Fresenius, Gilead, Janssen, Merck, Mundipharma, Mitsubishi Tanabe, and Retrophin; and has received grant support from AbbVie, AstraZeneca, Boehringer Ingelheim, and Janssen.",
year = "2022",
month = may,
day = "3",
doi = "https://doi.org/10.3389/fphar.2022.915713",
language = "English",
volume = "13",
journal = "Frontiers in pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
}